Skip to main content
. 2013 Sep;6(7):401–412.

Table 4.

Targeted Drugs and Market Failure: Change in the Use of Isosorbide Dinitrate Alone, Hydralazine Hydrochloride Alone before versus after Market Introduction of BiDil

Isosorbide dinitrate use only, before vs after introduction of BiDil
Patients Region Total use, %
(N = 288,559)
Northeast, % Midwest, % South, % West, %
Female
Black
2.19 vs 0.0 0.0 vs 0.41 0.0 vs 0.0 0.0 vs 0.0 0.49 vs 0.05
Nonblack 0.13 vs 0.01 0.26 vs 4.02 3.0 vs 2.8 0.49 vs 0.0 0.31 vs 2.35
Male
Black
1.7 vs 0.0 0.0 vs 0.0 0.0 vs 0.0 0.0 vs 0.0 0.47 vs 0.0
Nonblack 0.0 vs 0.63 0.02 vs 1.42 0.37 vs 0.0 0.02 vs 0.0 0.13 vs 0.38
Hydralazine hydrochloride use only, before vs after introduction of BiDil
Patients Region Total use, %
(N = 322,130)
Northeast, % Midwest, % South, % West, %
Female
Black
0.0 vs 0.0 0.0 vs 0.39 0.0 vs 0.0 0.0 vs 0.0 0.0 vs 0.05
Nonblack 0.0 vs 1.37 0.44 vs 0.13 0.0 vs 2.28 1.19 vs 0.0 0.42 vs 1.35
Male
Black
9.80 vs 14.74 0.010 vs 0.0 0.56 vs 2.30 0.0 vs 0.0 3.12 vs 2.03
Nonblack 3.95 vs 0.0 2.11 vs 0.0 0.26 vs 0.21 0.0 vs 0.0 1.23 vs 0.09
BiDil or isosorbide dinitrate/hydralazine hydrochloride use, before vs after introduction of BiDil
Patients Region Total use, %
(N = 14,247)
Northeast, % Midwest, % South, % West, %
Female
Black
0.0 vs 0.0 0.0 vs 7.40 0.0 vs 0.72 0.0 vs 0.0 0.0 vs 1.44
Nonblack 0.0 vs 0.0 0.0 vs 0.0 0.0 vs 0.02 0.0 vs 0.0 0.0 vs 0.01
Male
Black
0.0 vs 7.23 0.0 vs 0.0 0.03 vs 0.002 0.59 vs 0.0 3.96 vs 0.27
Nonblack 0.0 vs 0.0 0.0 vs 0.0 0.0 vs 0.02 0.0 vs 0.01 0.0 vs 0.01

NOTE: Use of drugs indicated for heart failure as reported in National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey data.